Dora Dias-Santagata

Plain English
This study looked at two rare skin tumors that combine features of basal cell carcinoma and melanoma in elderly men. The researchers found distinct types of cells in both tumors, with one tumor showing a mix of these cancer types and specific genetic changes associated with cancer progression. Notably, in the first case, they identified 11 shared genetic variants and amplified genes linked to melanoma growth. Who this helps: This information benefits doctors and researchers by improving understanding of these uncommon tumors and guiding treatment decisions for affected patients.

Plain English
Researchers studied a rare type of tumor called DICER1-related primitive polyphenotypic neoplasm, which can occur in the female reproductive system and abdomen. They found 15 cases of this tumor in patients aged 10 to 77, with many showing specific cell features that made them difficult to identify. Understanding these tumors is important because recognizing their unique characteristics can lead to better diagnosis and genetic testing, especially for younger patients who may have inherited risks.

Plain English
This study focused on undifferentiated melanoma, a type of skin cancer that doesn't show common markers usually associated with melanoma, making it hard to diagnose. Researchers looked at 27 cases and found that undifferentiated melanomas have unique gene expression patterns compared to typical melanomas. They discovered that the gene HMGA2 is significantly more active in undifferentiated melanoma, making it a reliable marker for diagnosing this challenging type of cancer. Who this helps: This helps patients with undifferentiated melanoma by improving diagnostic accuracy.

Plain English
This study looked at a rare type of uterine tumor that has characteristics similar to Wilms tumors, which are usually found in kidneys. Researchers found that of the eight patients studied, four had specific genetic mutations (DICER1 mutations) linked to these tumors. Their findings showed that these tumors often had complex structures and various cell types, and that outcomes varied: while one patient with a non-mutated tumor died within 9 months, three patients with DICER1 mutations were still alive after more than two and a half years. Who this helps: This study helps doctors understand and better treat patients with these unusual tumors.

Plain English
This study looked at a group of patients with specific types of brain tumors called gliomas that were genetically altered in a way related to a protein called FGFR. Researchers found that among 31 patients, those with a type of aggressive glioma called glioblastoma lived an average of 2.75 years, even though many had tumor characteristics that typically suggest a poorer outlook. The findings indicate that patients with these FGFR-altered tumors might live longer than expected, but surgery can remove these alterations, which affects the potential use of FGFR-targeting treatments. Who this helps: This helps patients with FGFR-altered gliomas and doctors treating them.

Plain English
Researchers studied four unusual ovarian tumors with specific genetic changes, finding that they were often mistakenly identified as other types of tumors. All cases shared distinct physical characteristics and genetic markers that set them apart. This matters because recognizing these tumors correctly can improve diagnosis and treatment options for patients, as they may not respond the same way as more common tumor types.

Plain English
This research studied a specific type of mesenchymal tumors that have changes in a gene called GLI1. Out of 16 tumors analyzed, 15 had a genetic fusion involving GLI1, with a median age of patients being 40 years, and some tumors had been present for over 10 years. The findings show that these tumors can have a more aggressive nature than previously thought, with half of the patients developing distant metastases, highlighting the need for careful monitoring similar to what is done for sarcomas. Who this helps: This helps doctors in treating patients with these specific types of tumors.

Plain English
This research studied how well a test for PTEN protein can identify Cowden syndrome (CS), a genetic condition linked to a higher risk of cancer. The study analyzed 45 tumors from 30 patients with CS and found that the PTEN test was very effective: it correctly identified 43 out of 45 tumors associated with CS (a sensitivity of 96%) and distinguished them from non-CS tumors 97% of the time. This is important because it could provide an easy and affordable way for doctors to screen for CS and catch related cancers early. Who this helps: This helps patients at risk for Cowden syndrome by enabling early detection and management of associated cancers.

Plain English
This study focused on a rare type of skin cancer known as penile melanoma, examining 8 cases to understand their characteristics and genetic makeup. Researchers found that most patients were older men, with average tumor depths of about 5.25 mm. Among the findings, 71% of the cases had key genetic changes, and survival rates were significantly lower for patients with certain cancer stages, especially those with spread to lymph nodes or distant sites. Who this helps: This research helps doctors and patients by providing better insights into the prognosis of penile melanoma and suggesting a new way to stage this cancer for more accurate treatment planning.

Plain English
This study examined a rare type of cancer in the tongue of a 46-year-old man, which was driven by a specific genetic mutation known as the FUS::CREM fusion. The tumor was about 4 cm in size and displayed aggressive features, although it had not spread to nearby lymph nodes. After surgery and radiation treatment, the patient showed no signs of the cancer returning after four months. Who this helps: This information is valuable for doctors treating patients with rare head and neck cancers.

Plain English
Researchers looked at 5,030 thyroid cancer samples and found 17 tumors with mutations in a specific gene family—11 where this mutation was the main cancer driver and 6 where it was a secondary mutation that might help cancer resist treatment. They discovered that some of these mutations could be targeted with existing drugs, but doctors aren't currently looking for them because they're not well-known. This matters because identifying these mutations in thyroid cancer patients could open up new treatment options that don't work for other types of thyroid cancer, potentially improving outcomes for people who have these specific mutations.

Plain English
This study looked at four patients with hormone receptor-positive metastatic breast cancer who had a specific genetic alteration called an ESR1 fusion. The research found that these patients might respond well to a treatment strategy involving CDK4/6 inhibitors, which could be effective against their unique genetic changes. Knowing about ESR1 fusions is important as it can help doctors tailor more effective treatments for these patients, improving their care. Who this helps: Patients with hormone receptor-positive metastatic breast cancer.

Plain English
This study looked at the genetic differences between two types of skin cancers: Merkel cell carcinomas that do not have a virus called Merkel cell polyomavirus (MCPyV) and neuroendocrine carcinomas (NECs). The researchers found that MCPyV-negative Merkel cell carcinomas often had certain mutations—like in the NF1 and PIK3CA genes—while NECs more frequently had mutations in the KRAS gene. These findings help doctors better differentiate between these cancers, which can lead to more accurate diagnoses and better treatment plans. Who this helps: This helps doctors and patients by improving cancer diagnosis and treatment options.

Plain English
This study explored a genetic condition called FOXC1 haploinsufficiency syndrome, which can cause eye problems and various physical issues. Researchers examined two adult women with this condition, who both had eye abnormalities, joint issues, and were shorter than average, among other symptoms. They found specific genetic changes in both patients—one had a complex deletion involving several genes, while the other had a mutation resulting in an early stop in protein production—revealing that this genetic change not only leads to eye problems but also affects overall health in multiple ways. Who this helps: This research benefits patients with FOXC1 haploinsufficiency and their doctors by providing clearer information about the symptoms and genetic causes of their condition.

Plain English
Researchers studied a type of thyroid cancer called Hürthle cell carcinoma, which has specific genetic changes that affect energy production in cells. They discovered that these cancer cells are particularly vulnerable to stress from certain harmful molecules due to their genetic makeup. This finding is important because it could lead to new treatments that target this weakness, potentially improving outcomes for patients with this type of cancer.

Plain English
Researchers created a fast-track program to quickly identify a specific genetic mutation in lung cancer patients and get them the right drug (osimertinib) as fast as possible by having radiologists, pathologists, and pharmacists work in parallel instead of sequentially. The program cut the time from taking a tissue sample to getting test results down to just 1 day (versus 17 days in normal workflows) and reduced the time from diagnosis to starting treatment from over a year to just 5 days, with some patients receiving the drug within 24 hours of confirmation. This matters because patients with this specific mutation respond much better to osimertinib than standard chemotherapy, so reducing delays by months or even weeks can significantly improve their chances of survival.

Plain English
This study examined a type of cancer called low-grade endometrial stromal sarcoma, specifically looking at a variant that has features similar to sex cord tissues. Researchers found a unique genetic fusion (PHF1-JAZF1) combined with deletions in the genes, which made the usual diagnostic test misleading; it looked like there was no fusion when there actually was. This is important because it shows that doctors need to consider both the physical appearance of the tumor and genetic tests together to make an accurate diagnosis. Who this helps: This helps doctors and pathologists who diagnose and treat patients with endometrial stromal sarcomas.

Plain English
This study looked at a rare type of acute myeloid leukemia (AML) linked to a specific genetic change called t(4;12)(q12;p13). Researchers found that patients with this change do not actually have a widely assumed fusion gene (ETV6-PDGFRA), and those who received the standard treatment, imatinib, based on this assumption did not respond—none of them showed improvement. The findings emphasize the need for precise genetic testing to ensure the right treatment is given, as those with this form of AML require different therapy options. Who this helps: This helps patients with t(4;12)(q12;p13) AML by ensuring they receive appropriate treatments.

Plain English
This research paper focused on understanding advanced thyroid cancer and how to treat it effectively using targeted therapies. The expert panel created 20 guiding statements based on current knowledge and practices, helping define what qualifies as advanced thyroid cancer and the role of genetic testing in treatment. This information is crucial because it helps doctors make informed decisions about the best treatment options for patients suffering from this challenging condition. Who this helps: This helps patients with advanced thyroid cancer and their doctors.

Plain English
This study focused on improving how healthcare providers use molecular tests for cancer patients through standardized procedures called "precision oncology workflows." After implementing these workflows, the research found that requests for tests in gastrointestinal (GI) patients increased by 17%, and adherence to recommended testing rose by 9%, with no negative impact on treatment; only 3 out of 1,088 patients were treated based on non-recommended tests. This is important because it shows that improved workflows can enhance cancer care without causing harm. Who this helps: Patients with gastrointestinal cancers benefit from more accurate and standardized testing.

Plain English
This study looked at gene fusions in melanoma, a type of skin cancer, to see how they could impact treatment options. Researchers analyzed 750 melanoma samples and found that gene fusions were rare, occurring in only 2% of cases, but 75% of those were potentially treatable with targeted therapies. Notably, fusions were more common in tumors lacking typical mutations, with significant findings for those with TERT promoter mutations. Who this helps: This research benefits melanoma patients, particularly those with advanced disease who have not responded to standard immunotherapy.

Plain English
This study looked at a rare type of thyroid cancer called thyroblastoma, which has unusual features similar to undeveloped thyroid tissue. Researchers examined two female patients, aged 19 and 45, who had large thyroid lumps and found that the tumors showed a specific structure and certain genetic mutations linked to the disease. Understanding this cancer better is important because it may help doctors identify and diagnose thyroblastoma more accurately, potentially improving treatment for those affected. Who this helps: Patients with thyroblastoma and their doctors.

Plain English
Researchers tested 8,106 tumors to see if a genetic change called MAML2 could help doctors diagnose mucoepidermoid carcinoma, a type of salivary gland cancer that's often confused with a more dangerous cancer called adenosquamous carcinoma. They found that MAML2 testing was present in most head and neck cancers (about 6% of them) and correctly identified mucoepidermoid carcinoma 60% of the time, but more importantly, it was excellent at ruling out the aggressive adenosquamous carcinoma—meaning it changed the diagnosis in nearly a quarter of cases. This test is most useful for confirming a suspected diagnosis or ruling out the more dangerous cancer type, which helps doctors make sure patients get the right treatment.

Plain English
This study focused on a type of skin cancer called Merkel cell carcinoma of unknown primary (MCC-UP), which occurs without a visible primary tumor. Researchers compared the characteristics of different groups of these tumors and found that the tumors without the Merkel cell polyomavirus (MCPyV) had specific UV damage signatures, while those with MCPyV showed a stronger immune response. They discovered that both types of cancers had significant immune activity, with MCPyV-positive tumors showing high levels of immune markers compared to typical cases of cutaneous MCC. Who this helps: This research helps doctors better understand and treat patients with Merkel cell carcinoma by identifying the characteristics of the tumors.

Plain English
This study explored a rare type of thyroid cancer called cribriform-morular thyroid carcinoma by examining 33 tumors from various patients. Researchers found that these tumors typically occurred in younger women aged 18 to 59, were mostly well-defined, and had sizes ranging from 0.1 to 8.0 cm. They also noted that these tumors have unique characteristics that suggest they are different from more common types of thyroid cancer. Who this helps: This helps patients with this specific type of thyroid cancer and doctors diagnosing and treating them.

Plain English
This study focused on a rare type of salivary gland cancer called mucoacinar carcinoma, a variation of mucoepidermoid carcinoma. Researchers examined 11 cases, finding that most tumors (10 out of 11) were located in the parotid gland, with an average tumor size of 1.8 centimeters. They identified different grades of cancer: 3 low grade, 7 intermediate grade, and 1 high grade, which is important for understanding the behavior and treatment options for this disease. Who this helps: This information benefits doctors diagnosing and treating patients with this specific type of salivary gland cancer.

Plain English
This study examined the impact of specific gene mutations on the survival of patients with mucosal melanomas, a rare form of skin cancer found in areas like the nose and vagina. Out of 214 cases analyzed, mutations were found in notable percentages: 19% had a specific mutation, and those with a certain genetic change were likely to have a worse survival outlook compared to those without it. This research is important because it helps identify which patients might have a more aggressive form of cancer, allowing for better treatment decisions. Who this helps: This benefits patients with mucosal melanomas and their doctors.

Plain English
Researchers studied a type of salivary gland cancer called intraductal carcinoma (IC) that has a specific genetic change known as NCOA4-RET. They found that this variant of IC can look similar to another cancer type, making it easy to misdiagnose. This is important because accurately identifying these cancers can lead to better treatment options for patients.

Plain English
This study looked at how changes in a type of genetic material found in blood, known as ctDNA, can help predict how well patients with advanced gastrointestinal cancers are responding to treatment. Researchers followed 138 patients and found that a decrease of 30% or more in ctDNA levels after four weeks of treatment was linked to better outcomes, with patients achieving this reduction living about 175 days without their cancer worsening compared to 59.5 days for those who didn't see such a drop. This finding is important because it suggests that monitoring ctDNA can give doctors earlier and more accurate signals about how a treatment is working, potentially helping them make better decisions for patient care. Who this helps: Patients with metastatic gastrointestinal cancer.

Plain English
Researchers studied a 73-year-old man with an advanced form of thyroid cancer called anaplastic thyroid carcinoma (ATC) that had not responded to traditional treatments. They used a method called next-generation sequencing to find specific genetic changes in his tumor, which included a gene fusion. The patient then received a targeted treatment called LOXO-292, and it worked well for him, resulting in a significant improvement that lasted over 19 months. Who this helps: This helps patients with anaplastic thyroid carcinoma who have limited treatment options.

Plain English
This study looked at a rare type of thyroid cancer that has specific genetic changes called NTRK rearrangements. Researchers examined 11 cases and found that most tumors showed aggressive growth and metastasized to lymph nodes, but importantly, none of the patients died from the disease after a median follow-up of 44 months. Three patients were treated with a targeted therapy for these genetic changes, and one patient experienced complete tumor resolution while the others showed significant reductions in their cancer. Who this helps: This research benefits patients with NTRK-rearranged thyroid cancer and the doctors treating them.

Plain English
This study looked at 62 cases of thyroid cancers that have specific genetic changes called kinase fusions. Researchers found that most of these cancers (95%) invaded blood vessels, and many (79%) had spread to nearby lymph nodes. The study highlights the importance of recognizing certain growth patterns in tumors to guide genetic testing and treatment, improving care for patients with thyroid cancer that does not respond to standard treatments. Who this helps: This helps patients with aggressive thyroid cancers by informing better treatment options.

Plain English
This study looked at a type of tumor called thymoma, specifically the more aggressive types B2 and B3. Researchers found a common genetic change, a recurrent gene fusion, in 4% of all thymomas, and in 6% of the aggressive B2 and B3 types, involving 11 patients. This discovery is important because it helps us better understand these tumors and could lead to new treatment options for patients who don't respond well to standard therapies. Who this helps: This benefits patients with thymoma, especially those with aggressive forms of the disease.

Plain English
This study looked at patients with papillary thyroid cancer, which is a common type of thyroid cancer. Researchers found that patients with a BRAF mutation faced a higher chance of their cancer coming back—about 18.6% compared to 9.9% for those without the mutation. Understanding this link matters because it can help doctors decide how often certain patients should be checked for cancer recurrence, ensuring high-risk patients get the attention they need while reducing unnecessary checks for low-risk patients. Who this helps: This benefits doctors and patients with papillary thyroid cancer by improving follow-up care.

Plain English
This study looked at secretory carcinoma, a type of low-grade cancer in the salivary glands, to identify new genetic changes that could impact treatment. Researchers found that, in addition to the known ETV6-NTRK3 gene fusion, some tumors also had another fusion called ETV6-RET, while others had a different change involving NCOA4-RET. These findings matter because they suggest new genetic targets for treatments that could help patients with this type of cancer. Who this helps: This helps patients with secretory carcinoma by opening up potential new treatment options.

Plain English
This study looked at patients with a specific type of lung cancer that has an EGFR mutation and found that about 3% to 10% of them can change into small-cell lung cancer. The researchers examined 67 patients and discovered that, on average, this transformation happens 17.8 months after the initial diagnosis. While treatments like platinum-etoposide and taxanes worked well, immunotherapy did not help anyone in this group. Who this helps: This information benefits doctors and researchers working with lung cancer patients.

Plain English
This study looked at blood cancers called myeloproliferative neoplasms (MPNs) to understand the role of a specific gene mutation called SF3B1. Researchers found that 10% of the cases had this mutation, which was often linked to a type of MPN called primary myelofibrosis. While these mutations didn’t lead to significant changes in blood counts, recognizing them is important to ensure patients receive the correct diagnosis and treatment, especially since misdiagnosis could affect their care. Who this helps: This helps patients with myeloproliferative neoplasms and their doctors.

Plain English
This study focused on a rare type of cancer called adenoid cystic carcinoma (ACC), which often affects salivary glands. Researchers tested 181 patients and found that 75% of those with tumors that couldn’t be surgically removed had genetic changes that could be targeted with specific therapies. Additionally, the testing showed that the methods used were financially viable, with 63% of costs covered by insurance. Who this helps: This benefits patients with adenoid cystic carcinoma and their doctors by providing better treatment options and insights into the disease.

Plain English
This study looked into how certain changes in a specific cell signaling pathway (PI3K/AKT/mTOR) affect the growth and severity of oligodendroglioma, a type of brain tumor. Researchers found that all six tumors with these pathway changes could successfully grow in lab mice, while none of the nine tumors without these changes could, highlighting a clear link. Importantly, the tumors with these mutations were sensitive to specific treatments that target this pathway, suggesting new potential therapies for more aggressive forms of the disease. Who this helps: Patients with progressive oligodendrogliomas may benefit from targeted therapies based on these findings.

Plain English
Researchers studied the impact of a gene mutation called PIK3CA on glioblastoma, a type of brain cancer, by looking at 157 patients. They found that 8.3% of these patients had this mutation, which was linked to younger age and more advanced disease when diagnosed, as well as shorter survival times—median progression-free survival was 6.9 months for those with the mutation compared to 12.4 months for others. This is important because it helps identify patients with a potentially more aggressive form of the disease, informing treatment decisions and future research. Who this helps: This helps patients with glioblastoma and their doctors.

Plain English
This study looked at the EWSR1 gene, which can connect with different genes in various tumors, to see how often these connections happen and what they mean for diagnosis and treatment. Over three years, researchers tested 63 patients and found 24 were positive for EWSR1 gene fusions using two testing methods. They identified three new gene connections that had not been reported before, which could help doctors make better treatment decisions for patients with specific cancers. Who this helps: Patients with EWSR1-related cancers.

Plain English
This study compared two methods of testing for cancer resistance: liquid biopsy, which analyzes DNA from a blood sample, and standard tissue biopsy, which takes a sample from a tumor. Researchers looked at 42 patients with gastrointestinal cancers who showed resistance to treatment. They found that liquid biopsies identified important resistance changes in 78% of cases that standard tissue biopsies missed, showing that cancer can have many different forms within the same patient. Who this helps: This helps patients with gastrointestinal cancers by providing better detection methods for treatment resistance.

Plain English
This study looked at two different ways to find resistance in tumors and understand their differences in gastrointestinal cancers: through liquid biopsy (a blood test) and tissue biopsy (a sample from the tumor). The research did not provide specific results due to an amendment, but comparing these methods is important for better treatment strategies. Understanding how tumors change over time can lead to more effective therapies for patients. Who this helps: Patients with gastrointestinal cancers.

Plain English
This study looked at a woman with endometrial cancer that had a specific genetic weakness and assessed her response to a treatment called pembrolizumab. After starting the treatment, she experienced a complete remission, meaning her cancer largely disappeared. This is important because it shows that patients with endometrial cancer who have genetic defects may greatly benefit from this type of immunotherapy. Who this helps: This helps patients with advanced endometrial cancer, particularly those with specific genetic mutations.

Plain English
Researchers studied how lung cancer cells respond to a new drug called nazartinib, which targets specific mutations that cause resistance to earlier treatments. They found that in two patients, cancer cells with different genetic traits, both sensitive and resistant to the drug, were present at the same time, which led to varied responses to the treatment. This is important because understanding these mixed responses can help doctors develop better treatment plans for patients with resistant lung cancers. Who this helps: This helps patients with lung cancer and their doctors.

Plain English
This study looked at 41 patients with non-small cell lung cancer (NSCLC) who developed resistance to a treatment called osimertinib. Researchers found that a specific genetic change, known as a fusion, was responsible for this resistance in some cases. They showed that using a combination of osimertinib and another drug, BLU-667, was effective and well-tolerated by two patients, who saw a quick positive response in their tumors. Who this helps: This research benefits patients with NSCLC who experience resistance to standard treatments.

Plain English
This study explored how artificial intelligence (AI) can assist doctors in deciding which genetic variants to report from complex test results in cancer care. The researchers developed an AI tool that analyzes data from nearly 20,000 genetic variants and found it was very accurate, with low false negativity (only 1%) and false positivity (2%). This matters because it can help doctors make better, more informed decisions about patient care in oncology by simplifying the interpretation of complex genetic information. Who this helps: This helps patients undergoing genetic testing for cancer, as well as the doctors who treat them.

Plain English
This study looked at a faster way to identify specific mutations in advanced lung cancer patients so they can start targeted therapy more quickly. Researchers found that using a rapid testing method identified mutations in 18% of patients and reduced the time to start treatment from 14 days with standard testing to just 7 days. This is important because earlier treatment can improve patient outcomes and the rapid method proved to be both effective and financially sustainable. Who this helps: This helps patients with advanced lung cancer who need quick access to effective therapies.

Plain English
Researchers studied Hürthle cell carcinoma (HCC), a type of thyroid cancer that doesn’t respond well to typical treatment. They found specific genetic changes in the cancer cells, including mutations in key genes and significant loss of genetic material, which were present even as the cancer spread. These discoveries highlight how HCC is genetically different from other thyroid cancers and may lead to better treatment options in the future. Who this helps: This helps patients with Hürthle cell carcinoma and their doctors.